Malignant Vulvar Neoplasm
Associated Genetic Biomarkers
There is 1 clinical trial for malignant vulvar neoplasm, of which 1 is open and 0 are completed or closed. Of the trial that contains malignant vulvar neoplasm as an inclusion criterion, 1 is phase 1 (1 open).
TREM1 is the most frequent gene inclusion criterion for malignant vulvar neoplasm clinical trials .
Py159 and pembrolizumab are the most common interventions in malignant vulvar neoplasm clinical trials.
Significant Genes in Malignant Vulvar Neoplasm
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for malignant vulvar neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant vulvar neoplasm as inclusion criteria, 1 is phase 1 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.